Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $35
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $30 to $35.
Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $30 to $35.